MEMBERS PRESENT
Kate Foster, RN, Diabetes Prevention Coordinator, Mt. Baker Foundation
Norris Kamo, MD, MPP, Virginia Mason Medical Center (chair)
Mamantha Palanati, MD, Kaiser Permanente
Nicole Treanor, MS, RD, CD, CDCES, Virginia Mason Franciscan Health
Robert Mecklenburg, MD, Virginia Mason (retired)
Susan Buell, YMCA of Tacoma Pierce County

STAFF AND MEMBERS OF THE PUBLIC
Emily Nudelman, DNP, RN
Karie Nicholas, MA, G.C., Bree Collaborative

WELCOME
Dr. Emily Nudelman, Bree Collaborative, welcomed everyone to the Bree Diabetes Care workgroup. The group reviewed the July meeting minutes and approved of the minutes.

DISCUSS: POPULATION HEALTH & COMMUNITY ENGAGEMENT RECOMMENDATIONS
Dr. Nudelman reviewed the document on Population Health & Community Engagement recommendations developed by the Diabetes Population Health Sub-committee. Through discussion, group will include information on other blood sugar monitoring tests; review literature on efficacy on different program delivery modalities (e.g., in-person, virtual, asynchronous and hybrid), co-pay as a barrier to care, mobile health services, and Medicaid recommendation of six visits; and add section for purchasers. The sub-committee will continue to meet to work on the discussed areas to add literature and make edits according to conversation today. The sub-committee will re-present information at the September meeting.

DISCUSS: MEDICATION
Dr. Norris Kamo continued the groups conversation from last month on Medication, supplies, and equipment designated as recommended by 2023 ADA Standards shall not be subject to pre-authorization and when prescribed for patients who meet inclusion criteria with [type] diabetes. Dr. Robert Mecklenburg reviewed the document on medications for diabetes and the classes of medications that are recommended by the group to be covered without prior-authorization, and without a co-pay or deductible. These medication classes are: insulin, metformin, ACE inhibitors, angiotensin receptor blockers, aspirin, Beta-blockers with proven cardiovascular outcomes benefit, diuretics, and moderate-intensity statin. For the section on devices and supplies the group will refer to the HTCC for guidance. The group will continue discussion on which medications to include within these classes, medications related to obesity management, and review other processes besides Prior authorization (e.g., gold card) for patient to receive medication and prove appropriateness for individual.
DISCUSS: GROUP TIMELINE

Dr. Nudelman reviewed with the group that commonly workgroups end at the end of the year. However, they may go longer as needed by the group and related to the cadence of the Bree Member meetings to approve of report for public comment and publication. As the report is open to receive public comment, Bree staff would like to work with the workgroup to discuss implementation and metrics.

PUBLIC COMMENT AND GOOD OF THE ORDER

At the next workgroup meeting, the workgroup will continue to refine current recommendations on Population Health and Community Engagement recommendations and further discuss medication recommendations. The workgroup’s next meeting will be on Thursday, September 14th from 8:00 – 9:30 AM.